

DRUG DISCOVERY TODAY**Editorial****Editor:** Steve Carney**Content Development Manager:** Pien van Spijker**Journal Manager:** Bharathi Sims**Publisher:** Fernanda Ogochi**Editorial Enquiries:***Drug Discovery Today*

Elsevier

125 London Wall, London, EC2Y 5AS, UK

Tel: +44 (0) 20 8439 5525

Fax: +44 (0)1865 853067

Email: ddt@drugdiscoverytoday.com

ADVISORY EDITORIAL BOARD**Jürgen Bajorath** *University of Bonn, Germany***Walter Blackstock** *Experimental Therapeutics
Centre, Singapore***David Brayden** *University College Dublin, Ireland***Paul Caron** *Integrated Profiling, USA***David Cavalla** *Numedix Ltd., UK***David Clark** *Argenta Discovery, UK***Dalia Cohen** *ALN Associates, USA***Donald Daley** *Argenta Discovery, UK***Sean Ekins** *Collaborations in Chemistry, USA***Hans-Peter Fischer** *GeneData, Switzerland***Peter Ghazal** *University of Edinburgh, UK***Christopher M. Hill** *Merck, USA***Nick Hird** *Takeda Chemical Industries, Japan***Enoch Huang** *Pfizer, USA***Thomas Joos** *University of Tuebingen, Germany***Vincent H.L. Lee** *Chinese University of Hong Kong,
China***David Lewin** *Yale University, USA***Christopher A. Lipinski** *Meliior Discovery, USA***Lorenz Mayr** *AstraZeneca, UK***Nick Meanwell** *Bristol-Myers Squibb, USA***BK Muralidhara** *Accelaron Pharma Inc, USA***Mark Murcko** *Disruptive Biomedical, LLC, USA***Fajun Nan** *Shanghai Institute of Materia Medica,
China***Pradeep Nathan** *Experimental Medicine, GSK and
University of Cambridge***Gitte Neubauer** *Cellzome, Germany***Eric Neumann** *Clinical Semantics Group Consulting,
USA***Tim Peakman** *UK Biobank, UK***Norton Peet** *Microbiotix, Inc., USA***Manuel Peitsch** *Swiss Institute of Bioinformatics,
Switzerland***Kurt Rasmussen** *Eli Lilly and Co. Ltd., USA***Janice Reichert** *Reichert Biotechnology Consulting
LLC, MA, USA***John Reidhaar-Olson** *Albert Einstein College of
Medicine, New York, USA***Mike Romanos** *Crescendo Biologics, Cambridge, UK***Raymond C. Rowe** *Intelligensys, UK***Andreas Russ** *University of Oxford, UK***Esther Schmid** *EFS Strategy and Business Consulting,
UK***Jonathan Sheldon** *Translational Medicine, Oracle,
UK***Michael Snyder** *Stanford University, USA***Susie Stephens** *Johnson & Johnson, USA***Robert Strausberg** *Ludwig Institute for Cancer
Research, New York, USA***Yuichi Sugiyama** *University of Tokyo, Japan***David Szymkowski** *Xencor, USA***Nick Terrett** *Ensemble Discovery, USA***Vladimir Torchilin** *Northeastern University, Boston,
USA***Mark Whittaker** *Evotec OAI, UK***Hans Winkler** *Janssen Pharmaceutica, Belgium***Limsoon Wong** *National University of Singapore***X.F. Steven Zheng** *Robert Wood Johnson Medical
School, USA*

DRUG DISCOVERY TODAY

REVIEWS (continued)

1295 Targeting mRNA translation in Parkinson's disease*Daniilo Correddu and Ivanhoe K.H. Leung***1304 Collaborative drug discovery and the Tres Cantos Antimalarial Set (TCAMS)***Alvaro Cortes Cabrera***1311 Bicyclic peptides: types, synthesis and applications***Shahrazad Ahangarzadeh, Mohammad M. Kanafi, Simzar Hosseinzadeh, Ahad Mokhtarzadeh, Mahmood Barati, Javad Ranjbari and Lobat Tayebi***FORTHCOMING ARTICLES:****Müller cells as a target for retinal therapy.***By Joke Devoldere, Karen Peynshaert, Stefaan C. De Smedt, Katrien Remaut.***Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties.***By Astrid Subrizi, Eva M. del Amo, Viktor Korzhakov-Vlakh, Tatiana Tennikova, Marika Ruponen and Arto Urtti.***Modified cells as potential ocular drug delivery systems.***By Tatiana Tennikova¹ and Arto Urtti***Connexin43 hemichannels: a potential drug target for the treatment of diabetic retinopathy.***By Odunayo O. Mugisha, Colin R. Green, Jie Zhang, Monica L. Acosta and Ilva D. Rupenthal.*